Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.
You may also be interested in...
FDA Requests Withdrawal Of Makena And Generics
Preterm birth prevention drug should come off the market to ensure the accelerated approval pathway does not operate as a lower approval standard, agency says; proposed withdrawal comes almost a year after an advisory committee split on the question of whether Makena should stay on the market in light of delayed, and ultimately unsuccessful, confirmatory study.
Accelerated Approval: US FDA Request For Makena’s Withdrawal Goes Beyond Failed Confirmatory Trial
Preterm birth prevention drug should come off the market to ensure the accelerated approval pathway does not operate as a lower approval standard, agency says; proposed withdrawal comes almost a year after an advisory committee split on the question of whether Makena should stay on the market in light of delayed, and ultimately unsuccessful, confirmatory study.
House Approps Bill Would "Harden" Science Requirements For FDA Rules, Guidance
Provision meant to protect ranchers/farmers could unleash Pandora's box of impediments to regulations, guidance; panel debates Avastin.